Hereditary Angioedema (HAE) Treatment Market CAGR Status Forecast 2022 – 2030
Acumen Research and Consulting has recently published a research report on the Hereditary Angioedema (HAE) Treatment Market for the forecast period of 2022-2030, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Hereditary Angioedema (HAE) Treatment Market offers an extensive analysis of how the Hereditary Angioedema (HAE) Treatment Market landscape would evolve through 2026. A deep dive study on this industry has enabled our research analysts to precisely analyze the Hereditary Angioedema (HAE) Treatment Market size. Additionally, our Hereditary Angioedema (HAE) Treatment Market forecast numbers have been updated on account of the impact COVID-19 pandemic and this has helped us to estimate the final worldwide Hereditary Angioedema (HAE) Treatment Market value.
The research study on the Hereditary Angioedema (HAE) Treatment Market analyzes key drivers upholding product sales and prominent trends shaping the growth of the market. The research study not only focuses on the latent opportunities for the key stakeholders of the market but also sheds light on the notable developments and future scope for innovation in the landscape
Download Sample Report Copy Of This Report From Here: https://www.acumenresearchandconsulting.com/request-sample/2460
The report starts with a quick executive summary, wherein, key takeaways have been highlighted for the readers to have a sneak peek at the key market segments. In addition, the research study also focuses on Hereditary Angioedema (HAE) Treatment Market trends that are responsible for market growth. The research study by Acumen Research and Consulting on the market also talks about the macroeconomic and microeconomic factors having deep-rooted influences on global Hereditary Angioedema (HAE) Treatment Market growth. The research study on the Hereditary Angioedema (HAE) Treatment Market industry analysis also offers a regional analysis, wherein, demand across every region has been comprehensively analyzed.
Our Hereditary Angioedema (HAE) Treatment Market regional outlook will allow you to comprehend information on a worldwide level. Besides that, it will make you easily uncover the Hereditary Angioedema (HAE) Treatment Market shares of all the segmentations and regions.
Key Vendors Included as below:
Key companies profiled in this report involve BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Pharming Group NV, CSL Limited, Takeda Pharmaceutical Company Limited., Attune Pharmaceuticals., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, and among others.
Key Questions Answered in the Report
The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-
- What is the overall structure of the market?
- What was the historical value and what is the forecasted value of the market?
- What are the key product level trends in the market?
- What are the market level trends in the market?
- Which of the market players are leading and what are their key differential strategies to retain their stronghold?
- Which are the most lucrative regions in the market space?
Hereditary Angioedema (HAE) Treatment Market Segmentation for this report is as below:
Market By Drug Class
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others
Market By Treatment Type
Prophylaxis
On-demand
Market By Route of Administration
Intravenous
Subcutaneous
Oral
Table of Content:
CHAPTER 1. Industry Overview of Hereditary Angioedema (HAE) Treatment
1.1. Definition and Scope
1.1.1. Definition of Hereditary Angioedema (HAE) Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Hereditary Angioedema (HAE) Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Hereditary Angioedema (HAE) Treatment Market By Drug Class
1.2.3. Hereditary Angioedema (HAE) Treatment Market By Treatment Type
1.2.4. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
1.2.5. Hereditary Angioedema (HAE) Treatment Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Hereditary Angioedema (HAE) Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Hereditary Angioedema (HAE) Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Hereditary Angioedema (HAE) Treatment Major Manufacturers in 2019
CHAPTER 5. Hereditary Angioedema (HAE) Treatment Market By Drug Class
5.1. Introduction
5.2. Hereditary Angioedema (HAE) Treatment Revenue By Drug Class
5.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast, By Drug Class, 2016-2027
5.2.2. C1-esterase inhibitor
5.2.2.1. C1-esterase inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Bradykinin B2 receptor antagonist
5.2.3.1. Bradykinin B2 receptor antagonist Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Kallikrein inhibitor
5.2.4.1. Kallikrein inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Others
5.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Hereditary Angioedema (HAE) Treatment Market Revenue By Treatment Type
6.1. Introduction
6.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Treatment Type
6.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
6.2.2. Prophylaxis
6.2.2.1. Prophylaxis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. On-demand
6.2.3.1. On-demand Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
7.1. Introduction
7.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Route of Administration
7.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
7.2.2. Intravenous
7.2.2.1. Intravenous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Subcutaneous
7.2.3.1. Subcutaneous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Oral
7.2.4.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Hereditary Angioedema (HAE) Treatment Market By Country
8.1. North America Hereditary Angioedema (HAE) Treatment Overview
8.2. U.S.
8.2.1. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.2. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.2.3. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.3. Canada
8.3.1. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.2. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.3.3. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Hereditary Angioedema (HAE) Treatment Market By Country
9.1. Europe Hereditary Angioedema (HAE) Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.2. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.2.3. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.3. Germany
9.3.1. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.2. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.3.3. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.4. France
9.4.1. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.2. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.4.3. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.5. Spain
9.5.1. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.2. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.5.3. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.2. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.6.3. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Hereditary Angioedema (HAE) Treatment Market By Country
10.1. Asia Pacific Hereditary Angioedema (HAE) Treatment Market Overview
10.2. China
10.2.1. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.2.2. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.2.3. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.3. Japan
10.3.1. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.3.2. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.3.3. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.4. India
10.4.1. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.4.2. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.4.3. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.5. Australia
10.5.1. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.5.2. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.5.3. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.6. South Korea
10.6.1. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.6.2. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.6.3. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.7.2. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.7.3. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Hereditary Angioedema (HAE) Treatment Market By Country
11.1. Latin America Hereditary Angioedema (HAE) Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.2.2. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.2.3. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
11.3. Mexico
11.3.1. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.3.2. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.3.3. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.4.2. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.4.3. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
CHAPTER 12. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market By Country
12.1. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.2.2. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.2.3. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
12.3. UAE
12.3.1. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.3.2. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.3.3. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.4.2. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.4.3. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
CHAPTER 13. Player Analysis Of Hereditary Angioedema (HAE) Treatment
13.1. Hereditary Angioedema (HAE) Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Hereditary Angioedema (HAE) Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. BIOCRYST PHARMACEUTICALS, INC.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. BIOCRYST PHARMACEUTICALS, INC. 2019 Hereditary Angioedema (HAE) Treatment Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. Ionis Pharmaceuticals
14.3. Pharming Group NV
14.4. CSL Limited
14.5. Takeda Pharmaceutical Company Limited.
14.6. Attune Pharmaceuticals.
14.7. Adverum Biotechnologies, Inc.
14.8. KalVista Pharmaceuticals
14.9. Others
Ask Query Here: sales@acumenresearchandconsulting.com
To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/2460
About Us
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
USA: +13474743864
India: +918983225533
E-mail: sales@acumenresearchandconsulting.com
